Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Learn everything you need to know about Sitagliptin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions ...

Millions of people with Type 2 diabetes rely on the drug, sitagliptin, to keep high blood sugar levels in check. Merck markets the drug as Januvia and Janumet. Last year, sitagliptin generated ...

Sitagliptin and its fixed-dose combinations support the heart and kidneys by protecting beta cells and are safe for older individuals and those with kidney or liver ailments. Sitagliptin and its ...

Merck’s MRK stock was up 3.5% on Thursday after a U.S. district court ruled in its favor in a patent infringement lawsuit against Viatris VTRS related to sitagliptin. Sitagliptin is the active ...

Treatment modalities for advanced solid pseudopapillary tumor of the pancreas. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...

(File) Sitagliptin, an anti-diabetic drug, sold under the brand name Januvia and is used to treat Type 2 diabetes. In July this year, the drug lost its patent. Usually, loss of patent means a fall ...

Mumbai: Merck’s Januvia/Janumet (Sitagliptin) patent expiry has led to India's drug price regulator National Pharmaceutical Pricing Authority (NPPA) fixing the prices of fixed-dose combinations ...

Bristol laboratories (gliclazide) (confidentiality agreement not signed, not participating) Brown and Burk UK (gliclazide, glimepiride, metformin, pioglitazone) (confidentiality agreement not signed, ...

(MINT_PRINT) The government on Friday launched diabetes drug Sitagliptin and its combinations at rates as low as ₹60 per pack of ten, which will reportedly be sold at generic pharmacy stores ...

(FE.com) Glenmark Pharmaceuticals Limited (Glenmark) on Thursday announced that it has launched sitagliptin and its Fixed Dose Combinations (FDCs) for adults with Type 2 diabetes in India.